Back to top
more

ASLAN Pharmaceuticals (ASLN)

(Delayed Data from NSDQ)

$0.47 USD

0.47
1,010,847

0.00 (0.21%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $0.49 +0.02 (4.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

by Zacks Equity Research

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.

ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

by Zacks Equity Research

ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.

Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now

by Zacks Equity Research

Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.

ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study

by Zacks Equity Research

ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.

Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.

Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

by Zacks Equity Research

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Atreca, Inc. (BCEL) have performed compared to their sector so far this year.

Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Apexigen, Inc. (APGN) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.

Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now

by Zacks Equity Research

ASLAN Pharmaceuticals Ltd. (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year.

DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

by Zacks Equity Research

The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly

by Zacks Equity Research

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

by Zacks Equity Research

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

by Zacks Equity Research

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.

Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe

by Zacks Equity Research

Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.

Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth

by Zacks Equity Research

Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.

AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie

by Zacks Equity Research

AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.

Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474

by Zacks Equity Research

Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.

Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis

by Zacks Equity Research

The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.

Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab

by Zacks Equity Research

Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.

BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201

by Zacks Equity Research

The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Stock up.

Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study

by Zacks Equity Research

Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.

Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia

by Zacks Equity Research

The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.

BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics

by Zacks Equity Research

BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.